Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors

por Buzatto, I.P.C., Ribeiro-Silva, A., Andrade, J.M., Carrara, H.H.A., Silveira, W.A., Tiezzi, D.G.
Publicado 2017